Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.
Curious about the stocks that are showing activity after the closing bell on Tuesday? The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals STOKE THERAPEUTICS (
NASDAQ:STOK ) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's strategy.
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
